Theriva Biologics Statistics
Total Valuation
TOVX has a market cap or net worth of $5.45 million. The enterprise value is -$4.67 million.
Important Dates
The last earnings date was Wednesday, May 14, 2025, before market open.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TOVX has 9.60 million shares outstanding. The number of shares has increased by 109.25% in one year.
| Current Share Class | 9.60M |
| Shares Outstanding | 9.60M |
| Shares Change (YoY) | +109.25% |
| Shares Change (QoQ) | +146.20% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 0.44% |
| Float | 2.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.08 |
| P/TBV Ratio | 0.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.15 |
| Quick Ratio | 1.97 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -87.31% and return on invested capital (ROIC) is -37.47%.
| Return on Equity (ROE) | -87.31% |
| Return on Assets (ROA) | -25.85% |
| Return on Invested Capital (ROIC) | -37.47% |
| Return on Capital Employed (ROCE) | -67.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.17M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.94% in the last 52 weeks. The beta is 1.14, so TOVX's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -93.94% |
| 50-Day Moving Average | 1.18 |
| 200-Day Moving Average | 2.00 |
| Relative Strength Index (RSI) | 24.35 |
| Average Volume (20 Days) | 2,598,723 |
Short Selling Information
The latest short interest is 73,952, so 0.77% of the outstanding shares have been sold short.
| Short Interest | 73,952 |
| Short Previous Month | 79,024 |
| Short % of Shares Out | 0.77% |
| Short % of Float | 3.08% |
| Short Ratio (days to cover) | 3.29 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.73M |
| Pretax Income | -20.35M |
| Net Income | -25.65M |
| EBITDA | -18.59M |
| EBIT | -18.73M |
| Earnings Per Share (EPS) | -$19.03 |
Full Income StatementBalance Sheet
The company has $11.61 million in cash and $1.57 million in debt, giving a net cash position of $10.04 million or $1.05 per share.
| Cash & Cash Equivalents | 11.61M |
| Total Debt | 1.57M |
| Net Cash | 10.04M |
| Net Cash Per Share | $1.05 |
| Equity (Book Value) | 19.07M |
| Book Value Per Share | 6.85 |
| Working Capital | 8.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.94 million and capital expenditures -$1,000, giving a free cash flow of -$16.94 million.
| Operating Cash Flow | -16.94M |
| Capital Expenditures | -1,000 |
| Free Cash Flow | -16.94M |
| FCF Per Share | -$1.76 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |